Erschienen in:
18.12.2019 | Research Article
Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review
verfasst von:
D. Viñal, N. Rodriguez-Salas, P. Perez-Wert, O. Higuera, I. Ghanem, J. Feliu
Erschienen in:
Clinical and Translational Oncology
|
Ausgabe 8/2020
Einloggen, um Zugang zu erhalten
Abstract
Background
Capectiabine is an oral antineoplastic drug used in multiple malignancies. Proton pump inhibitors (PPI) have been proven to interact with other oral antineoplastic agents. In this systematic review we will summarize the clinical evidence on the efficacy of capecitabine when used concomitantly with PPI.
Materials and methods
We performed a systematic literature search on the main databases up to November 2019.
Results
Nine studies met our inclusion criteria: 8 retrospective studies and 1 phase II clinical trial. Patients with colorectal, breast and gastroesophageal were represented. Four out of the 9 studies reported a shorter efficacy outcome in uni- or multivariate analysis when capecitabine was taken concomitantly with PPI than alone.
Conclusions
Up to date, the clinical evidence reported on the use of capecitabine concomitantly with PPI is scarce and shows conflicting results. While awaiting further data, avoiding misuse of PPI in cancer patients taking capecitabine is recommended.